# Jiangsu Trautec Medical Technology Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/jiangsu-trautec-medical-technology-co

- Industry: Biotechnology
- Headquarters: Changzhou, China
- Website: www.trautec.com.cn/
- Total disclosed funding: $57M
- Latest round: Series B (Sep 18, 2023)
- Investors on record: 8

## About

Founded in 2015 and based in Changzhou, China, Jiangsu Trautec Medical Technology Co., Ltd. operates as a biomedical developer that focuses on recombinant collagen based biomaterials R&D. The company has R & D base and production plant located in Changzhou, Xining and Changsha. The company cooperates with Chinese University of Hong Kong, Shanghai Changhai Hospital, Shenzhen Bay laboratory Pingshan Center to laboratory and research institute. Jiangxia is the CTO of the company, and the total cost of the project he presided over exceeded HKD 10 million. Haihang Li is the CIO of the company and he participated in the national key research and development plan of the ministry of science and technology - stem cell and transformation research.

The company provides recombinant human-derived collagen products. The business of the company includes the development and production of recombinant collagen-based biomaterials. The company's products include recombinant type I collagen, recombinant type III collagen and recombinant type XVII collagen.

## Funding rounds

- Series B, Sep 18, 2023, $28M — L Catterton, MingFeng Capital, CLSA Asset Management Limited
- Series A, Aug 10, 2022, $30M — Boyu Capital, Holley Group Co., Ltd, CDH Baifu Capital, Huafang Capital, Shiseido Ziyue (Shanghai) Management Consulting

## Investors

- Boyu Capital (https://capitalatlas.ai/funds/boyu-capital) — Series A
- Holley Group Co., Ltd — Series A
- CDH Baifu Capital (https://capitalatlas.ai/funds/cdh-baifu-capital) — Series A
- Huafang Capital (https://capitalatlas.ai/funds/huafang-capital) — Series A
- Shiseido Ziyue (Shanghai) Management Consulting — Series A
- L Catterton (https://capitalatlas.ai/funds/l-catterton) — Series B
- MingFeng Capital — Series B
- CLSA Asset Management Limited — Series B